Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
2.

Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis.

Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, De Cobelli O, Artibani W, Cimino S, Morgia G, Damiano R, Nikolaou K, Kröger N, Stenzl A, Bedke J, Kruck S.

Prostate Cancer Prostatic Dis. 2018 Nov 28. doi: 10.1038/s41391-018-0113-2. [Epub ahead of print] Review.

PMID:
30487646
3.

Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.

Stühler V, Maas JM, Bochem J, da Costa IA, Todenhöfer T, Stenzl A, Bedke J.

World J Urol. 2018 Oct 29. doi: 10.1007/s00345-018-2538-6. [Epub ahead of print]

PMID:
30374610
4.

mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.

Rausch S, Schollenberger D, Hennenlotter J, Stühler V, Kruck S, Stenzl A, Bedke J.

J Cancer Res Clin Oncol. 2019 Jan;145(1):153-163. doi: 10.1007/s00432-018-2775-5. Epub 2018 Oct 27.

PMID:
30368665
5.

[Mode of action, new targets and potential biomarkers in modern immunotherapy].

Bedke J, Stühler V, Todenhöfer T, Stenzl A.

Urologe A. 2018 Nov;57(11):1301-1308. doi: 10.1007/s00120-018-0787-z. Review. German.

PMID:
30350128
6.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2018 Sep 12. pii: S1558-7673(18)30506-8. doi: 10.1016/j.clgc.2018.09.006. [Epub ahead of print]

PMID:
30341028
7.

Can contrast-enhanced ultrasound and acoustic radiation force impulse imaging characterize CT-indeterminate renal masses? A prospective evaluation with histological confirmation.

Thaiss WM, Bedke J, Kruck S, Spira D, Stenzl A, Nikolaou K, Horger M, Kaufmann S.

World J Urol. 2018 Oct 15. doi: 10.1007/s00345-018-2520-3. [Epub ahead of print]

PMID:
30324296
8.

Can urinary biomarkers replace cystoscopy?

Maas M, Bedke J, Stenzl A, Todenhöfer T.

World J Urol. 2018 Oct 3. doi: 10.1007/s00345-018-2505-2. [Epub ahead of print]

PMID:
30283995
9.

Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer.

Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Ladhar S, Kamjabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Frees S, Daugaard M, Oo HZ, Fisel P, Schwab M, Schaeffeler E, Douglas J, Hennenlotter J, Bedke J, Gibb EA, Fazli L, Stenzl A, Black PC.

Mol Cancer Ther. 2018 Dec;17(12):2746-2755. doi: 10.1158/1535-7163.MCT-18-0107. Epub 2018 Sep 27.

PMID:
30262589
10.

Transketolase like 1 (TKTL1) expression alterations in prostate cancer tumorigenesis.

da Costa IA, Hennenlotter J, Stühler V, Kühs U, Scharpf M, Todenhöfer T, Stenzl A, Bedke J.

Urol Oncol. 2018 Oct;36(10):472.e21-472.e27. doi: 10.1016/j.urolonc.2018.06.010. Epub 2018 Aug 16.

PMID:
30119993
11.

Systemic Alterations of Wnt Inhibitors in Patients with Prostate Cancer and Bone Metastases.

Aufderklamm S, Hennenlotter J, Leidenberger P, Rausch S, Hohneder A, Kühs U, Maas M, Schwentner C, Bedke J, Stenzl A, Todenhöfer T.

Dis Markers. 2018 Jul 18;2018:1874598. doi: 10.1155/2018/1874598. eCollection 2018.

12.

Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling.

Leuthold P, Schwab M, Hofmann U, Winter S, Rausch S, Pollak MN, Hennenlotter J, Bedke J, Schaeffeler E, Haag M.

J Proteome Res. 2018 Sep 7;17(9):3039-3049. doi: 10.1021/acs.jproteome.8b00199. Epub 2018 Aug 23.

PMID:
30091608
13.

Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.

Reustle A, Fisel P, Renner O, Büttner F, Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, Fend F, Stenzl A, Bedke J, Schwab M, Schaeffeler E.

Int J Cancer. 2018 Dec 15;143(12):3181-3193. doi: 10.1002/ijc.31741. Epub 2018 Sep 25.

PMID:
30070687
14.

Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma.

Büttner F, Winter S, Rausch S, Hennenlotter J, Kruck S, Stenzl A, Scharpf M, Fend F, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E.

BMC Med. 2018 Jul 5;16(1):108. doi: 10.1186/s12916-018-1088-5.

15.

Single-use versus reusable ureterorenoscopes for retrograde intrarenal surgery (RIRS): systematic comparative analysis of physical and optical properties in three different devices.

Deininger S, Haberstock L, Kruck S, Neumann E, da Costa IA, Todenhöfer T, Bedke J, Stenzl A, Rausch S.

World J Urol. 2018 Dec;36(12):2059-2063. doi: 10.1007/s00345-018-2365-9. Epub 2018 Jun 5.

PMID:
29869701
16.

Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons.

Neumann E, Mayer J, Russo GI, Amend B, Rausch S, Deininger S, Harland N, da Costa IA, Hennenlotter J, Stenzl A, Kruck S, Bedke J.

Eur Urol Focus. 2018 May 22. pii: S2405-4569(18)30101-9. doi: 10.1016/j.euf.2018.04.011. [Epub ahead of print]

PMID:
29802051
17.

[Overview of treatment of localized and metastatic renal cell carcinoma (RCC)].

Stühler V, Bedke J.

MMW Fortschr Med. 2018 May;160(8):45-51. doi: 10.1007/s15006-018-0014-2. German. No abstract available.

PMID:
29721911
18.

Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.

Maas M, Walz S, Stühler V, Aufderklamm S, Rausch S, Bedke J, Stenzl A, Todenhöfer T.

Expert Rev Mol Diagn. 2018 May;18(5):443-455. doi: 10.1080/14737159.2018.1469979.

PMID:
29707982
19.

Cognitive versus Software-Assisted Registration: Development of a New Nomogram Predicting Prostate Cancer at MRI-Targeted Biopsies.

Kaufmann S, Russo GI, Thaiss W, Notohamiprodjo M, Bamberg F, Bedke J, Morgia G, Nikolaou K, Stenzl A, Kruck S.

Clin Genitourin Cancer. 2018 Aug;16(4):e953-e960. doi: 10.1016/j.clgc.2018.03.013. Epub 2018 Apr 3.

PMID:
29685613
20.

No influence of smoking status on the performance of urine markers for the detection of bladder cancer.

Deininger S, Hennenlotter J, Rausch S, Docktor K, Neumann E, da Costa IA, Bedke J, Stenzl A, Todenhöfer T.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1367-1373. doi: 10.1007/s00432-018-2639-z. Epub 2018 Apr 19.

PMID:
29675793

Supplemental Content

Loading ...
Support Center